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Overexpression of cyclin Di correlates with early
recurrence in superficial bladder cancers
KY Shin1, G Kong2, WS Kim2, TY Lee1, YN Woo1 and JD Lee2
Departments of 'Urology and 2Pathology, College of Medicine, Hanyang University, 17, Haengdang-dong, Sungdong-ku, Seoul 133-791, Korea
Summary Cyclin Dl is a cell cycle regulator essential for G1 phase progression and is frequently overexpressed in several human tumour
types as a consequence of gene amplification or chromosomal rearrangements. We analysed the expression of cyclin Dl in 75 patients with
transitional cell carcinoma (TCC) to investigate the possible relationship between its expression and clinical outcome as well as
histopathological findings using the immunohistochemical method. We observed strong staining (++, > 50% positive cells) for cyclin Dl in 19
cases (25.3%) and weak staining (+, 5-50% positive cells) in 19 cases (25.3%). Overexpression of cyclin Dl was not associated with tumour
invasion. No significant association was found between overexpression of cyclin Dl and tumour grade (P > 0.05). We assessed the
differences of disease-free interval in superficial tumours and actuarial survival probability in invasive tumours according to the status ofcyclin
Dl expression. Tumours with (++) staining for cyclin Dl recurred much more rapidly than (-) and/or (+) staining tumours (P< 0.01 for - vs ++;
P < 0.05 for + vs ++). However, overexpression of cyclin Dl was not associated with a shortened overall survival of patients with invasive
tumours (P< 0.1). These results suggest that genetic alteration of cyclin Dl appears to be an early event in thetumorigenesis of bladderTCC
and is associated with early recurrence in superficial tumours.
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Transitional cell carcinoma ofthe urinary bladder, like many other
types of solid tumours, is expected to arise through a series of
genetic changes that lead to tumourprogression. The identification
of the molecular events underlying urothelial cell transformation
may not only expand our understanding of the natural history of
the disease but may also present useful prognostic markers and
potential targets for therapy.
Recent evidence suggests that amplification ofthe 11q13 region
is involved in avariety ofhuman tumours, including bladder carci-
noma (Proctor et al, 1991; Bringuier et al, 1996), head and neck
squamous cell carcinoma (Michalides et al, 1995) and carcinomas
of the oesophagus and breast (Lammie et al, 1991; Jiang et al,
1992; Michalides et al, 1996). In the amplified 11q13 region,
several genes have been identified, of which cyclin Dl is most
consistently amplified and overexpressed (Schuuring etal, 1992a).
Cyclins are thought to be essential proteins in cell cycle regulation
because oftheir specific and periodic expression during cell cycle
progression (Evans et al, 1983). Binding of the cyclins with
cyclin-dependent kinase regulates their activity and contributes to
cell cycle regulation (Matsushime et al, 1992). Cyclin Dl is
encoded by the CCND1 gene on chromosome 11q13 (Inaba et al,
1992; Xiong et al, 1992a), which has been identified as the
PRADI proto-oncogene and the most likely candidate for the
BCL1 proto-oncogene (Motokura et al, 1991; Withers et al, 1991).
Several studies have addressed the clinical and prognostic
significance of amplification of 1lq13 loci. Amplification of
cyclin Dl appears to be correlated with poor prognosis in breast
carcinoma (Schuuring et al, 1992b), with lymph node involvement
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and recurrence in head and neck squamous cell carcinoma (Muller
et al, 1994; Parise et al, 1994; Michalides et al, 1995). Although
amplification of the 1 q13 region has been observed in bladder
carcinoma, the prognostic significance of cyclin Dl overexpres-
sion has not been yet reported in bladder carcinoma.
The purpose ofthis study was to detect the expression ofcyclin
DI in bladder carcinoma tissues and to investigate whether over-
expression of cyclin Dl is associated with poor prognosis in
patients with bladder carcinoma. For these purposes, we analysed
overexpression of cyclin Dl immunohistochemically and
reviewed the medical records of 75 patients retrospectively. The
relationship of cyclin Dl overexpression to selected clinical vari-
ables was also analysed.
MATERIALS AND METHODS
Patients
Primary bladder carcinomas from 75 patients were examined (age
range 30-83 years; average 62 years). The tumours were staged
according to the TNM pathological staging system (UICC, 1978),
and the histological grade was assessed according to Ash (1940).
The histopathological characteristics are summarized in Table 1.
Twenty of the 53 patients with superficial tumours had two or
more tumours initially, and concomitant Tis (carcinoma in situ)
lesions were not detected in the patients with superficial tumours.
All patients were treated with curative intent and had received no
prior therapy. Nine patients with solitary, low-grade and Ta
tumours were treated with transurethral resection (TUR) only.
Patients with multiple, high-grade Ta or TI tumours had received
intravesical chemotherapy with doxorubicin (37 cases) or BCG
(seven cases) after TUR. In 22 patients with invasive tumour, a
total of ten patients underwent radical cystectomy, seven patients
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Table 1 Comparison of cyclin Dl expression, stage and grade in 75 TCC patients
CD1-(%) CD1+(%) CD1 ++(%) Significance
Stage NS
Superficial 26 (49.0) 13 (24.5) 14 (26.4)
(Ta, T1)
Invasive 11 (50.0) 6 (27.3) 5 (22.7)
(T2, T3, T4 1)
Grade NS
11 19 (47.5) 13 (32.5) 8 (20.0)
III 14 (53.8) 6 (23.1) 6 (23.1)
IV 4 (44.4) 0 (0.0) 5 (55.6)
Total 37 19 19
TCC, transitional cell carcinoma; NS, not significant.
Table 2 Comparison of cyclin Dl expression, stage, grade, multiplicity and treatment in superficial bladder cancers
CD1-(%) CD1+(%) CD1 ++(%) Significance
Stage NS
Ta 4 (36.4) 3 (27.2) 4 (36.4)
Ti 22 (52.4) 10 (23.8) 10 (23.8)
Grade NS
Low (I, 11) 17 (47.2) 11 (30.6) 8 (22.2)
High (Ill, IV) 9 (52.9) 2 (11.8) 6 (35.3)
Multiplicity NS
Solitary 17(51.6) 8 (24.2) 8 (24.2)
Multiple 9 (45.0) 5 (25.0) 5 (30.0)
Treatment NS
TUR only 4 (44.4) 3 (33.3) 2 (22.2)
TUR + IVT 22 (50.0) 10 (22.7) 12 (27.3)
NS, not significant; TUR, transurethral resection; IVT, intravesical chemotherapy or immunotherapy.
Figure 1 Immunohistochemical staining of cyclin Dl in TCC of the urinary
bladder. Notice the specific and strong positive nuclear staining of the tumour
cells and the absence of staining in the stroma cells (x200)
received radiotherapy and five patients were treated with systemic
chemotherapy. Patients were followed up for a maximum of 79
months; the median follow-up time was 35 months.
Immunohistochemistry
All 75 resected specimens were fixed in 10% buffered formalin for
about 24 h, embedded in paraffin, and 5-jm thick sections were
then deparaffinized. After the sections were heated with a
microwave oven (containing 0.01 M sodium citrate buffer pH 6.0;
800 W), endogenous peroxidase was blocked with 3% hydrogen
methanol. The sections were washed three times with cold 0.5 M
tris-buffered saline (TBS). Inhibition ofnon-specific binding was
accomplished by incubation with normal goat serum (Dako,
Carpenteria, CA, USA) for 20 min. Monoclonal mouse anti-
humancyclin Dl oncoprotein antibody (1:20 dilution, Novocastra,
Newcastle, UK) was applied and incubated for 30 min. The
sections were then washed three times with TBS, followed by
incubation for 30 min with biotinylated antimouse IgG (Dako).
After washing, peroxidase-antiperoxidase conjugate (Dako) was
applied. They were then stained with diaminobenzidine tetra-
hydrochrolide (Dako) and counterstained with Meyer's haema-
toxylin. We used formalin-fixed, paraffin-embedded WI-38 cells
(ATCC, Rockville, MD, USA) for positive control. Negative
control sections were obtained by incubation with phosphate-
buffered saline instead of monoclonal cyclin DI antibody, and
they were consistently negative. Staining intensity was assessed as
follows: -, no cancer cells or less than 5% of the cancer cells
showed weak or ambiguous staining; +, less than 50% of the
BritishJournal ofCancer(1997) 75(12), 1788-1792 0CancerResearchCampaign 19971790 KYShin etal
Cu -a
a3
cu
cu .cn
co
a)
Cu)
~0
co
0
EL
D1 - (nr26)
------ CD1 + (n=13)
-CD1 ++ (n=14)
0 10 20 30 40 50 60 70
Months
80
Figure 2 Kaplan-Meier disease-free interval curves of 53 patients with
superficial bladder cancers. (-) vs (++) staining, P< 0.01; (+) vs (++)
staining, P < 0.05; (-) and (+) vs (++) staining, P < 0.005
cancer cells were stained; ++ more than 50% of the cancer cells
showed positive or strongly positive staining (Michalides et al,
1995). Only nuclear staining was observed.
Statistics
The chi-square test for trend was used to evaluate the statistical
significance of the relationship between staining and prognostic
variables. Survival curves were prepared using the method of
Kaplan and Meier (1958). The statistical analyses of the differ-
ences between curves were performed using the log-rank test (Peto
et al, 1977).
RESULTS
Immunohistochemical staining for cyclin Dl
Tumour cell nuclear staining of variable extent was noted in 38
tumours (50.6%), which could be readily divided into groups
showing weak (+) and strong staining (++) (Figure 1). Strong
staining was observed in 19 of 75 tumours (25%) and weak
staining was observed in a further 19 tumours (25%).
Analysis of staining for cyclin DI in relation to the clinico-
pathological characteristics of the patient population is shown in
Table 1. Staining for cyclin Dl was observed in 27 of 53 super-
ficial tumours (51%) and in 11 of 22 invasive tumours (50%).
Positive staining for cyclin DI was not associated with tumour
stage. Positive staining for cyclin DI was found in 21 of 40
(52.5%) well-differentiated tumours (grade I and II), 12 of 26
(46.2%) moderately well-differentiated tumours (grade III) and
five of nine (55.6%) poorly differentiated tumours (grade IV).
Thus, positive staining for cyclin DI was not also associated with
tumour grade (P > 0.05).
Table 2 shows cyclin DI expression in relation to stage, grade,
multiplicity and treatment in the 53 patients with superficial
bladder tumours. There was little difference in the staining for
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Figure 3 Kaplan-Meier disease-free interval curves of 44 patients with
superficial bladder cancer treated by intravesical chemotherapy or
immunotherapy after TUR. (-) vs (++) staining, P < 0.005; (+) vs (++)
staining, P < 0.05; (-) and (+) vs (++) staining, P < 0.005
cyclin D1 based on tumour invasiveness, grade, multiplicity and
treatment.
Prognostic significance of overexpression of cyclin Dl
in superficial tumours
Nine of 14 superficial tumours (64%) with strong staining for
cyclin DI recurred within 12 months. On the other hand, only 4 of
26 superficial tumours (15%) with negative staining and 2 of 13
superficial tumours (15%) with weak staining recurred within 12
months (CD1- vs ++, P < 0.01; + vs ++, P < 0.05; Figure 2). In
nine patients treated with TUR only, three recurred during the
follow-up period. Two cases with negative staining for cyclin Dl
recurred in the post-operative period at 22 months and 33 months
respectively, whereas one case with strong staining recurred in the
postoperative period at 6 months. In 44 patients with TUR and
intravesical doxorubicin or BCG therapy, 8 of 12 superficial
tumours (67%) with strong staining, 2 of 10 (20%) with weak
staining and 3 of 22 (14%) with negative staining recurred within
12 months (CD1 - vs ++, P < 0.005; + vs ++, P < 0.05, Figure 3).
Hence, superficial tumours recurred much more rapidly when the
primary tumours showed strong staining for cyclin DI compared
with primary tumours showing negative or weak staining, regard-
less oftreatment.
Prognostic significance of overexpression of cyclin Dl
in invasive tumours
We assessed the actuarial survival probability in the 22 patients
with invasive tumours according to the expression of cyclin Dl.
Three-year actuarial survival rate in the cases with negative
staining for cyclin D1 was approximately 65%. On the other hand,
in the patients with weak and strong staining for cyclin DI, 3-year
actuarial survival rate was about 26%. Thus, there was a tendency
for patients with stained tumours to have a poorer prognosis than
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Figure 4 Kaplan-Meier actuarial survival curves
bladder cancers. (-) vs (+) and (++) staining, P <
the patients with negatively stained tumoui
statistically significant association was obs
for cyclin Dl and actuarial survival in the
tumours (P < 0.1; Figure 4).
DISCUSSION
The involvement of the chromosome 11qI
human tumours has been described. Cyc
candidate oncogene on the 1lq13 amplic
consistently amplified and overexpresse
tumours (Schuuring et al, 1992a). Bind
cyclin-dependent kinases regulates their ac
cell cycle regulation (Kidd, 1991; Mal
Several lines of evidence lave sugges
involved in the G1 to S transition of the i
1991; Lew et al, 1992). Also, cyclin Dl i
regulation through interactions with pRb
related proteins, such as PCNA and p21 (F
et al, 1992b; Dowdy et al, 1993).
Several studies have reported the progn(
overexpression of cyclin Dl. In breast c
cyclin Dl has been related to poor prog
1992b). When studying squamous cell car
neck, amplification of cyclin Dl was asso(
involvement and an increased likelihood
(Muller et al, 1994; Parise et al, 1994; Mi
bladder cancer, pRb and various cell cycle
to be involved in tumour development ar
1991; Sakis et al, 1993). Furthermore, an
some 1 q13 has also been found in bladdi
Peters, 1991; Proctor et al, 1991; Bringu
findings suggest that alterations of cyclin
role in the development ofbladder cancer.
The present immunohistochemical stud'
pression of cyclin Dl in approximately ha
cancers. The reported frequency of amp]
region was about 10-15% in bladder can
Bringuieret al, 1996). There are no available data to explain this
difference in bladder cancer. However, Gillett et al (1994) have
shown that overexpression of cyclin Dl in breast tumours, as
detected by immunohistochemistry, occurred almost twice as
frequently as cyclin DI amplification. The possible explanation
for this discrepancy is that immunohistochemical overexpression
of cyclin Dl results from overall deregulation of cyclin Dl gene
expression as well as gene amplification.
We found that the frequency of overexpression of cyclin DI in
superficial tumours was almost identical to that in invasive
tumours. There was no statistically significant difference between
expression of cyclin DI and tumour grade, which is partly consis-
tent with the results of Proctor et al (1991), although they reported
that amplification at l1q13 showed no correlation with tumour
grade. Bringuier et al (1996) reported that low expression ofcyclin
Dl mRNA correlated with more aggressive TCC. In their report,
clear overexpression of cyclin DI mRNA was found in 81% of
50 60 70 80 superficial tumours and 38% of invasive tumours. Our immuno-
histochemical data, however, revealed that positive staining for
of 22 patients with invasive cyclin DI was found in 51% of superficial tumours and 50% of
0.1 invasive tumours. Thus our immunohistochemical results show
some discrepancy with the previous report of Bringuier et al
(1996). This discrepancy may be largely influenced by the rela-
rs for cyclin Dl. But no tively small groups oftumours studied and by the sensitivity ofthe
served between staining methods used to determine overexpression of cyclin Dl. Taken
e patients with invasive together, although the frequency of overexpression of cyclin Dl in
the present study was different to that reported by Bringuier et al
(1996), the results strongly indicate that genetic alterations of
cyclin Dl genes may be early events in the multistep carcino-
genesis of bladder tumours and are not involved in the develop-
13 region in a variety of ment of invasive tumours.
:lin Dl is a prominent Bladder cancer can be clinically classified into two groups:
-on, because it is most superficial tumours, which are localized in the mucosal or submu-
d in several types of cosal layer, and invasive tumours, which infiltrate into muscular or
ing of cyclin Dl with deeper layers. These two types of bladder cancer show signifi-
tivity and contributes to cantly different clinical behaviour. At initial presentation, approxi-
tsushime et al, 1992). mately 50-70% of bladder tumours are superficial. Although
ted that cyclin Dl is metastasis is less common with superficial bladder cancers, such
cell cycle (Xiong et al, tumours may progress and the majority will recur and require
s involved in cell cycle additional treatment. It is generally accepted that patients with TI,
) and other cell cycle- multiple, large or high-grade tumours are at greater risk of recur-
finds et al, 1992; Xiong rence (Heney et al, 1983; Wolf et al, 1985). In this study, we
assessed the probability of disease-free survival in the 53 super-
ostic significance of the ficial tumours according to the overexpression of cyclin Dl.
,ancer, amplification of Interestingly, superficial tumours recurred much more rapidly
nosis (Schuuring et al, when the tumours showed strong staining for cyclin Dl compared
*cinoma of the head and with tumours showing negative or weak staining. However, over-
,ciated with lymph node expression of cyclin Dl was not associated with tumour invasive-
of tumour recurrence ness, grade, multiplicity and treatment in superficial tumours. Our
chalides et al, 1995). In findings suggest that strong overexpression of cyclin Dl results in
-related proteins appear the rapid recurrence of a subset of superficial bladder cancers and
nd growth (Presti et al, serves as an independent prognostic factor for the prediction of
nplification of chromo- early recurrence in superficial tumours.
[er cancer (Lammie and With respect to prognosis, several reports on other types of
tier et al, 1996). These carcinoma have stressed that amplification and overexpression of
Dl play an important cyclin Dl correlates with poor prognosis (Borg et al, 1991;
Schuuring et al, 1992b; Muller et al, 1994). The present study
y demonstrated overex- shows that, in patients with invasive tumours, there was a
lf of 75 urinary bladder tendency for patients with overexpression of cyclin Dl to have a
lification of the 1lq13 worse prognosis than patients with negatively stained tumours for
icers (Schuuring, 1995; cyclin Dl, although the correlation between the overexpression of
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cyclin Dl and actuarial survival was not statistically significant.
The weak correlation found between expression of cyclin Dl and
actuarial survival in the present study of bladder cancer does not
exclude a potential role as a prognostic factor. To investigate this
possibility, further studies based on larger numbers of cases with
complete follow-up data will be needed.
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